Nov 11, 2019   SOURCE: BusinessWire

Echosens at VA’s National Veterans Small Business Engagement Meeting: Demonstrating FibroScan Benefits for Early Detection and Monitoring of Liver Disease

Echosens, a high-technology company offering the FibroScan family of products, will provide a live demonstration of a FibroScan examination, in partnership with Fidelis, at the Department of Veterans Affairs’ (VA) National Veterans Small Business Engagement, Dec. 10-11, Nashville, Tennessee, booth #305. The VA now includes in its contract with Echosens the FibroScan 430 mini+ portable technology as part of its strategy to improve access to non-invasive liver assessment and early detection of asymptomatic non-alcoholic fatty liver disease (NAFLD).

“The adoption of FibroScan among two-thirds of the VA hospitals has truly been impressive,” says Jon Gingrich, CEO, Echosens North America. “VA physicians can now treat veterans with a noninvasive liver diagnostic tool to assess and monitor the patients’ liver stiffness and fat. We are pleased to participate at this important national VA medical device meeting to share this essential technology for assessing a potentially progressive liver disease that occurs in the veteran population with high blood sugar, obesity or high cholesterol.”

The FibroScan examination is a simple, non-invasive test that provides scores that can be used to diagnose and monitor liver health, providing immediate results for the treating clinician. The addition of portable FibroScan systems will enable the VA to reach deeper into the community, saving time, money and, most importantly, reducing the healthcare burden on our veterans.

“With one-third of veterans receiving their healthcare in community clinics and not the VA Medical Centers, the addition of the FibroScan 430 mini+ provides greater access to care for these patients,” says Gingrich.

Dustin Lee, owner and president, Fidelis Sustainability Distribution, LLC, USMC scout sniper veteran and principal, states, “FibroScan served as a valuable tool in the VA’s successful efforts of nearly 100 percent hepatitis C eradication within the VA. As part of an overall assessment, FibroScan can help detect liver disease before it progresses and becomes symptomatic, reducing costs and improving outcomes.”

To learn more about NAFLD and the VA, download our white paper “Aligning with the Veterans Administration to Battle Chronic Liver Disease.”

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. https://echosens.us/learn-more/